Grace Therapeutics, Inc. Deferred Income Tax Liabilities, Net
Grace Therapeutics, Inc. (GRCE) had Deferred Income Tax Liabilities, Net of $612.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-13
- 2026-06-30: Deferred Income Tax Liabilities, Net $612.00K.
- 2026-03-31: Deferred Income Tax Liabilities, Net $612.00K.
- 2025-12-31: Deferred Income Tax Liabilities, Net $2.31M.
- 2025-09-30: Deferred Income Tax Liabilities, Net $2.31M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $612.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $612.00K 10-Q · filed 2026-08-13 |
| 2025-12-31 | $2.31M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $2.31M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.31M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $2.31M 10-K · filed 2026-06-18 |
| 2024-12-31 | $3.33M 10-Q · filed 2025-02-13 |
| 2024-09-30 | $3.94M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $4.79M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.51M 10-K · filed 2025-06-23 |
| 2023-12-31 | $6.40M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $6.61M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $7.06M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $7.35M 10-K · filed 2024-06-21 |
| 2022-12-31 | $16.22M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $16.49M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $16.65M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $16.89M 10-K · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |